Internal Medicine 1, Faculty of Medicine, Shimane University, Izumo, Japan.
Department of Diabetology and Endocrinology, Kanazawa Medical University, Uchinada, Japan.
J Diabetes Investig. 2020 May;11(3):516-526. doi: 10.1111/jdi.13219. Epub 2020 Mar 11.
N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) is an endogenous peptide that has been confirmed to show excellent organ-protective effects. Even though originally discovered as a modulator of hemotopoietic stem cells, during the recent two decades, AcSDKP has been recognized as valuable antifibrotic peptide. The antifibrotic mechanism of AcSDKP is not yet clear; we have established that AcSDKP could target endothelial-mesenchymal transition program through the induction of the endothelial fibroblast growth factor receptor signaling pathway. Also, recent reports suggested the clinical significance of AcSDKP. The aim of this review was to update recent advances of the mechanistic action of AcSDKP and discuss translational research aspects.
N-乙酰丝氨酰-天冬氨酰-赖氨酰-脯氨酸（AcSDKP）是一种内源性肽，已被证实具有出色的器官保护作用。尽管最初被发现作为造血干细胞的调节剂，但在最近的二十年中，AcSDKP 已被认为是一种有价值的抗纤维化肽。AcSDKP 的抗纤维化机制尚不清楚；我们已经确定 AcSDKP 可以通过诱导内皮成纤维细胞生长因子受体信号通路来靶向内皮-间充质转化程序。此外，最近的报告还表明了 AcSDKP 的临床意义。本综述的目的是更新 AcSDKP 的作用机制的最新进展，并讨论转化研究方面。
